Clinical Trial Update: Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating cabozantinib in combination with nivolumab and ipilimumab for previously untreated advanced or metastatic renal cell carcinoma; the tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)
• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Exelixis | Conditions: Renal Cell Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-09-10